Keyword: Sutent

Pfizer has long been kidney cancer player, but it’s looking to take things up a notch with its latest immunotherapy data.

Seventeen cancer drugs from global and local drugmakers take an average 56.7% discount to win spots on China's insurance scheme.

Targeted by the Justice Department in an industrywide copay assistance investigation, Pfizer has now agreed to a $23.85 million deal with the feds.

Pfizer has been looking to expand Inlyta's use to kidney cancer patients at a high risk of disease recurrence after surgery—but it's fallen short.

With Tecentriq and Avastin's trial win over Sutent in first-line kidney cancer, Roche scored new points in its quest to advance the combo.

Pfizer’s old dog Sutent has shown it has one more trick to perform as a renal cancer treatment before being passed up by the new breed of I-O drugs.

Pfizer is counting on a new approval for Sutent, its kidney cancer drug, but an FDA advisory panel isn’t so sure.

A one-two punch with Bristol-Myers' Opdivo and Yervoy cut the risk of death by 37% for kidney cancer patients with a poor prognosis.

Pfizer’s kidney-cancer fighter Sutent is an aging drug--but it may just have one more label expansion up its sleeve.